Comparative Effectiveness Study of Bubble CPAP Devices in the NICU
NCT ID: NCT02392806
Last Updated: 2018-03-09
Study Results
Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.
View full resultsBasic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
43 participants
INTERVENTIONAL
2015-01-31
2016-08-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Comparing Bubble and Ventilator Nasal CPAP in Preterm Infants
NCT02003846
Novel Low Cost Bubble CPAP as an Alternative Respiratory Support in Low Resource Setting
NCT06082674
"Effectiveness of Delivery Room Bubble CPAP in Preterm Infants With Respiratory Distress
NCT07162285
Immediate Treatment Outcomes of b-CPAP vs Oxygen Therapy in Preterm Babies Presenting With RDS at KCMC
NCT03620448
Surfactant Positive Airway Pressure and Pulse Oximetry Trial
NCT00233324
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Population: Infants born at \<=1250 grams birth weight but \>= 500 grams birth weight
Randomization: Equal allocation stratified by gestational age (\<27 weeks, \>=27 weeks)
Study diagram:
72h 24h X----------\>X1-----------\>Y2 Y----------\>Y1-----------\>X2 Infants will be randomly assigned to treatment X (BabiPlus, control group) or treatment Y (B\&B Bubbler, intervention group). The primary outcome is bubble CPAP failure during the first 72 hours following extubation, measured at time point 1 in the diagram. Bubble CPAP failure is defined as requiring re-intubation or non-invasive positive pressure ventilation (NIPPV), requiring FiO2 of \>60% for one hour or a pCO2 measurement of \>65 mm Hg. For those infants that remain on CPAP during the initial study period, the number that reach 21% inspired oxygen for \>12 consecutive hours will be compared between groups. This difference will also be analyzed using a Chi square test.
Those infants that remain on CPAP following the 72 hour initial study period (e.g., did not meet primary outcome criteria) will be crossed over to the opposite treatment arm for at least 24 hours. The minimum oxygen requirement required to keep the saturations in the ordered range, per standard NICU guidelines, will be recorded and compared between time points 1 and 2.
This study design is complex due to the nature of the disease of these patients. Each day every infant's premature pulmonary disease is evolving. There is no way to control for this.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
CROSSOVER
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
BabiPlus, Respiralogics
Infants randomized to the BabiPlus device will be extubated to BabiPlus Bubble CPAP device and after 72 hours, if the infant has remained extubated, will be crossed-over to the B\&B Bubbler device for 24 hours
Bubble CPAP- BabiPlus, Respiralogics
Infant will be randomized to BabiPlus Bubbler at time of extubation
B&B Bubbler, B&B medical Technologies
Infants randomized to the B\&B Bubbler device will be extubated to B\&B Bubbler Bubble CPAP device and after 72 hours, if the infant has remained extubated, will be crossed-over to the BabiPlus device for 24 hours
Bubble CPAP- B&B Bubbler, B&B Medical devices
Infant will be randomized to B\&B Bubbler at time of extubation
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Bubble CPAP- BabiPlus, Respiralogics
Infant will be randomized to BabiPlus Bubbler at time of extubation
Bubble CPAP- B&B Bubbler, B&B Medical devices
Infant will be randomized to B\&B Bubbler at time of extubation
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. Infant requires intubation for mechanical ventilation within the first 48 hours following delivery.
3. Infant has received exogenous surfactant during mechanical ventilation.
Exclusion Criteria
2. Congenital condition that precludes the use of CPAP (choanal atresia, diaphragmatic hernia, etc.)
3. Birth weight \>1250 grams or \<500 grams.
4. Non-English speaking parents. -
1 Day
100 Days
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Marya Strand, MD
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Marya Strand, MD
Associate Professor, Pediatrics
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Noah H Hillman, M.D.
Role: PRINCIPAL_INVESTIGATOR
Associate Director, Pediatrics
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Cardinal Glennon Children's Hospital
St Louis, Missouri, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
SLU Protocol # 24949
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.